Quick Takeaways: Why It Matters? The EUA makes ivermectin liquid a short-term, horse-only screwworm prophylaxis tool, adding another regulated option to the NWS armamentarium and slightly strengthening biosecurity for foals and wounded horses, but because protection lasts only 24 hours and...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways: Why It Matters? By extending Bravecto Quantum’s label to cover Asian longhorned and Gulf Coast ticks for a full 12 months, Merck further differentiates the product as the longest‑lasting, broadest‑spectrum injectable parasiticide available exclusively...
Quick Takeaways Why It Matters? Merck Animal Health strengthens its dermatology franchise with a differentiated, second-generation JAK inhibitor positioned as a convenient, first-line option for allergic pruritus. Once-daily dosing and rapid onset are likely to ...
Quick Takeaways: Why It Matters? Full approval elevates KBroVet from a conditional option to the reference standard for potassium bromide in canine idiopathic epilepsy, giving vets greater confidence in its long‑term use. Its once‑daily, chewable, liver...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
